School-Level Variation in Coverage of Co-Administered dTpa and HPV Dose 1 in Three Australian States.
adolescent vaccination
cancer prevention
differential uptake
evaluation and impact
implementation
school-based immunisation
vaccination
vaccine specific hesitancy
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
19 Oct 2021
19 Oct 2021
Historique:
received:
25
07
2021
revised:
14
09
2021
accepted:
08
10
2021
entrez:
26
10
2021
pubmed:
27
10
2021
medline:
27
10
2021
Statut:
epublish
Résumé
Australian adolescents are routinely offered HPV and dTpa (diphtheria, tetanus, pertussis) vaccines simultaneously in the secondary school vaccination program. We identified schools where HPV initiation was lower than dTpa coverage and associated school-level factors across three states. HPV vaccination initiation rates and dTpa vaccination coverage in 2016 were calculated using vaccine databases and school enrolment data. A multivariate analysis assessed sociodemographic and school-level factors associated with HPV initiation being >5% absolute lower than dTpa coverage. Of 1280 schools included, the median school-level HPV initiation rate was 85% (interquartile range (IQR):75-90%) and the median dTpa coverage was 86% (IQR:75-92%). Nearly a quarter (24%) of all schools had HPV vaccination initiation >5% lower than dTpa coverage and 11 % had >10% difference. School-level factors independently associated with >5% difference were remote schools (aOR:3.5, 95% CI = 1.7-7.2) and schools in major cities (aOR:1.8, 95% CI = 1.0-3.0), small schools (aOR:3.3, 95% CI = 2.3-5.7), higher socioeconomic advantage (aOR:1.7, 95% CI = 1.1-2.6), and lower proportions of Language-background-other-than-English (aOR:1.9, 95% CI = 1.2-3.0). The results identified a quarter of schools had lower HPV than dTpa initiation coverage, which may indicate HPV vaccine hesitancy, and the difference was more likely in socioeconomically advantaged schools. As hesitancy is context specific, it is important to understand the potential drivers of hesitancy and future research needs to understand the reasons driving differential uptake.
Sections du résumé
BACKGROUND
BACKGROUND
Australian adolescents are routinely offered HPV and dTpa (diphtheria, tetanus, pertussis) vaccines simultaneously in the secondary school vaccination program. We identified schools where HPV initiation was lower than dTpa coverage and associated school-level factors across three states.
METHODS
METHODS
HPV vaccination initiation rates and dTpa vaccination coverage in 2016 were calculated using vaccine databases and school enrolment data. A multivariate analysis assessed sociodemographic and school-level factors associated with HPV initiation being >5% absolute lower than dTpa coverage.
RESULTS
RESULTS
Of 1280 schools included, the median school-level HPV initiation rate was 85% (interquartile range (IQR):75-90%) and the median dTpa coverage was 86% (IQR:75-92%). Nearly a quarter (24%) of all schools had HPV vaccination initiation >5% lower than dTpa coverage and 11 % had >10% difference. School-level factors independently associated with >5% difference were remote schools (aOR:3.5, 95% CI = 1.7-7.2) and schools in major cities (aOR:1.8, 95% CI = 1.0-3.0), small schools (aOR:3.3, 95% CI = 2.3-5.7), higher socioeconomic advantage (aOR:1.7, 95% CI = 1.1-2.6), and lower proportions of Language-background-other-than-English (aOR:1.9, 95% CI = 1.2-3.0).
CONCLUSION
CONCLUSIONS
The results identified a quarter of schools had lower HPV than dTpa initiation coverage, which may indicate HPV vaccine hesitancy, and the difference was more likely in socioeconomically advantaged schools. As hesitancy is context specific, it is important to understand the potential drivers of hesitancy and future research needs to understand the reasons driving differential uptake.
Identifiants
pubmed: 34696310
pii: vaccines9101202
doi: 10.3390/vaccines9101202
pmc: PMC8537995
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Health and Medical Research Council
ID : APP1132344
Références
Hum Vaccin Immunother. 2014;10(9):2543-50
pubmed: 25483472
PLoS One. 2017 Aug 25;12(8):e0183725
pubmed: 28841681
Vaccine. 2013 Dec 31;31 Suppl 7:H1-31
pubmed: 24332295
Sex Transm Infect. 2010 Jun;86(3):181-6
pubmed: 19965802
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
BMJ Open. 2019 Jul 11;9(7):e029087
pubmed: 31300506
Expert Rev Vaccines. 2017 Nov;16(11):1107-1118
pubmed: 28914112
Epidemiol Infect. 2011 Mar;139(3):400-5
pubmed: 20334731
Sex Transm Infect. 2011 Jun;87(4):349-53
pubmed: 21357601
PLoS Med. 2010 May 04;7(5):e1000270
pubmed: 20454567
Heliyon. 2019 Oct 18;5(10):e02588
pubmed: 31692704
BMC Med. 2013 Oct 22;11:227
pubmed: 24148310
BMC Public Health. 2018 Dec 22;18(1):1402
pubmed: 30577816
Lancet Public Health. 2016 Nov;1(1):e8-e17
pubmed: 29253379
Hum Vaccin Immunother. 2013 Dec;9(12):2649-53
pubmed: 23982270
PLoS One. 2018 Feb 15;13(2):e0193054
pubmed: 29447271
J Glob Oncol. 2017 Mar 17;3(5):611-634
pubmed: 29094100
BMC Pediatr. 2017 Dec 01;17(1):200
pubmed: 29191180
Vaccine. 2019 Jul 26;37(32):4525-4532
pubmed: 31262584
Euro Surveill. 2014 Jan 16;19(2):
pubmed: 24457007
Aust N Z J Public Health. 2017 Oct;41(5):455-457
pubmed: 28664595
Pediatrics. 2011 Nov;128(5):830-9
pubmed: 22007006
Int Nurs Rev. 2012 Sep;59(3):305-11
pubmed: 22897180
Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:42-58
pubmed: 28986092
Lancet Oncol. 2012 Jun;13(6):607-15
pubmed: 22575588
Commun Dis Intell (2018). 2019 Sep 16;43:
pubmed: 31522666
J Adolesc Health. 2008 Oct;43(4 Suppl):S5-25, S25.e1-41
pubmed: 18809145
Sex Transm Dis. 2009 Jun;36(6):375-9
pubmed: 19556931
J Public Health (Oxf). 2016 Sep;38(3):569-577
pubmed: 26054910
F1000Res. 2017 Jun 12;6:866
pubmed: 28663791
Lancet Glob Health. 2016 Jul;4(7):e453-63
pubmed: 27340003
Papillomavirus Res. 2019 Dec;8:100170
pubmed: 31176807
BMJ. 2008 May 10;336(7652):1056-8
pubmed: 18436917
J Pediatr. 2010 Oct;157(4):617-22
pubmed: 20472250
Psychol Sci Public Interest. 2017 Dec;18(3):149-207
pubmed: 29611455
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
Lancet. 2019 Aug 10;394(10197):497-509
pubmed: 31255301
J Public Health (Oxf). 2014 Mar;36(1):36-45
pubmed: 23620542
Sex Transm Dis. 2010 Apr;37(4):234-9
pubmed: 19940807
Health Promot J Austr. 2019 Apr;30(2):143-152
pubmed: 30091836
Vaccine. 2013 Aug 20;31(37):3811-7
pubmed: 23777956
PLoS One. 2011 May 03;6(5):e19244
pubmed: 21559276
Expert Rev Vaccines. 2018 Sep;17(9):765-767
pubmed: 30079782
Eur J Contracept Reprod Health Care. 2009 Dec;14(6):399-405
pubmed: 19929642
Sex Transm Infect. 2011 Oct;87(6):458-63
pubmed: 21636616
Ann Epidemiol. 2009 Aug;19(8):531-8
pubmed: 19394865
J Epidemiol Community Health. 2014 Jun;68(6):571-7
pubmed: 24567443
Expert Rev Vaccines. 2018 Dec;17(12):1085-1091
pubmed: 30495978